Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Analysis for Therapy Choice (MATCH)
NCT02465060Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2015
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
A Phase 2 trial of afatinib, crizotinib, osimertinib, dabrafenib + trametinib, trametinib in solid tumor, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Started Aug 2015; status: active, not recruiting.
02
Drugs
03
Conditions
solid tumorlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT02465060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465060.